Don’t Look Back: US FDA AdComm Offers No Flexibility For Rexulti’s Post Hoc Bid In PTSD

 
• By Bridget Silverman
  
An FDA advisory committee voted against Otsuka's bid for brexpiprazole to become the first new therapy for post-traumatic stress disorder in more than 20 years. (Shutterstock)

More from US Advisory Committees

More from Product Reviews